Status:
RECRUITING
Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
Lead Sponsor:
Anthony Bai
Collaborating Sponsors:
Physician Services Incorporated
Canadian Institutes of Health Research (CIHR)
Conditions:
MRSA
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intravenous vancomycin is considered first line therapy for serious methicillin-resistant Staphylococcus aureus (MRSA) infections including bacteremia, central nervous system infection, pneumonia, ple...
Eligibility Criteria
Inclusion
- Adult patients with serious MRSA infections based on culture results including bacteremia, pneumonia, pleural space infection, central nervous system infection, bone infection, septic arthritis, prosthetic joint infection, and deep abscess
- Enrolment within 4 days from date of MRSA culture collection
- Patient either currently not on vancomycin or has received vancomycin for 4 days or less
Exclusion
- Vancomycin minimum inhibitory concentration (MIC) ≥2ug/mL
- Patient is palliative or expected to die in the next 48 hours, or requires critical care resources but will not receive it due to advanced care directives
- History of type 1 hypersensitivity reaction to vancomycin
- Patients on intermittent hemodialysis or peritoneal dialysis
Key Trial Info
Start Date :
March 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04793152
Start Date
March 20 2023
End Date
October 1 2029
Last Update
June 13 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton Health Sciences
Hamilton, Ontario, Canada, L8L 2X2
2
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 4A6
3
Kingston Health Sciences Centre
Kingston, Ontario, Canada, K7L 2V7
4
McGill University Health Centre
Montreal, Quebec, Canada, H3H 2R9